Title : Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.

Pub. Date : 2013

PMID : 23409026






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 After the recent approval of nilotinib, dasatinib, bosutinib and ponatinib for treatment of chronic myeloid leukemia along with imatinib, all of which vary in their effectiveness against mutated BCR-ABL forms, detection of pre-existing BCR-ABL mutations can help in selection of appropriate first-line drug therapy. Dasatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
2 After the recent approval of nilotinib, dasatinib, bosutinib and ponatinib for treatment of chronic myeloid leukemia along with imatinib, all of which vary in their effectiveness against mutated BCR-ABL forms, detection of pre-existing BCR-ABL mutations can help in selection of appropriate first-line drug therapy. Dasatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens